PT2796129E - Composição contendo palmitoiletanolamida ultramicronizada - Google Patents

Composição contendo palmitoiletanolamida ultramicronizada Download PDF

Info

Publication number: PT2796129E
Authority: PT; Portugal
Prior art keywords: ethanolamide; composition containing; containing ultra; palmitoyl; micronized
Prior art date: 2009-09-07

Application number

PT141574210T

Other languages

English (en)

Inventor

Francesco Della Valle

Gabriele Marcolongo

Maria Federica Della Valle

Original Assignee

Epitech Group S P A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-09-07

Filing date

2009-09-07

Publication date

2015-10-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42211652&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2796129(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-07 Application filed by Epitech Group S P A filed Critical Epitech Group S P A

2015-10-13 Publication of PT2796129E publication Critical patent/PT2796129E/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Zoology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Biophysics (AREA)
Reproductive Health (AREA)
Dispersion Chemistry (AREA)
Surgery (AREA)
Inorganic Chemistry (AREA)
Endocrinology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PT141574210T 2009-09-07 2009-09-07 Composição contendo palmitoiletanolamida ultramicronizada PT2796129E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/IT2009/000399 WO2011027373A1 (en)	2009-09-07	2009-09-07	Composition containing ultra-micronized palmitoyl - ethanolamide

Publications (1)

Publication Number	Publication Date
PT2796129E true PT2796129E (pt)	2015-10-13

Family

ID=42211652

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT141574210T PT2796129E (pt)	2009-09-07	2009-09-07	Composição contendo palmitoiletanolamida ultramicronizada
PT97414627T PT2475352E (pt)	2009-09-07	2009-09-07	Composição contendo palmitoiletanolamida ultramicronizada

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT97414627T PT2475352E (pt)	2009-09-07	2009-09-07	Composição contendo palmitoiletanolamida ultramicronizada

Country Status (14)

Country	Link
US (2)	US8470373B2 (pt)
EP (2)	EP2475352B2 (pt)
JP (1)	JP5746178B2 (pt)
KR (1)	KR101662871B1 (pt)
CN (2)	CN102186459A (pt)
AR (2)	AR078159A1 (pt)
AU (1)	AU2009352080B2 (pt)
BR (1)	BRPI0919753B8 (pt)
CA (1)	CA2738117C (pt)
CY (2)	CY1116695T1 (pt)
ES (2)	ES2547133T5 (pt)
PL (2)	PL2796129T3 (pt)
PT (2)	PT2796129E (pt)
WO (1)	WO2011027373A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2262763A2 (en)	2008-03-04	2010-12-22	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.	Compounds and methods of treating obesity
CN102186459A (zh)	2009-09-07	2011-09-14	晶源集团股份责任有限公司	含有超微粒化十六酰胺乙醇的组合物
US20150202179A1 (en) *	2012-07-20	2015-07-23	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Fatty acid derivatives for use in a method of treating depression and associated conditions
ITMI20130354A1 (it) *	2013-03-08	2014-09-09	Again Life Italia Srl	Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
ES2603809T3 (es)	2014-03-19	2017-03-01	Epitech Group S.R.L.	Composición farmacéutica que comprende palmitoiletanolamida y L-acetilcarnitina
HUE047471T2 (hu) *	2014-03-21	2020-04-28	Epitech Group S P A	N-acil-etanolaminokat tartalmazó szemészeti, intraartikuláris vagy intravesicalis készítmények
EP2944309B1 (en)	2014-05-14	2019-03-20	EPITECH GROUP S.p.A.	Use of palmitoylethanolamide in combination with opioids
PL2965765T3 (pl)	2014-07-08	2019-11-29	Epitech Group S P A	Zastosowanie adelmidrolu w leczeniu dysfunkcji nabłonka
ES2641143T3 (es)	2014-08-13	2017-11-07	Epitech Group S.P.A.	Una composición farmacéutica que comprende palmitoiletanolamida y citidina-difosfocolina
JP2015155412A (ja) *	2015-03-03	2015-08-27	エピテック・グループ・エス．アール．エル．	超微粉化パルミトイル−エタノールアミドを含む組成物
NL2014464B1 (en) *	2015-03-16	2017-01-13	Vanderbilt Science Holding Ltd	Composition for use in the treatment of neuropathic pain.
ES2935605T3 (es) *	2015-04-29	2023-03-08	Scisparc Ltd	Combinaciones de cannabinoides y N-aciletanolaminas
WO2016183134A1 (en) *	2015-05-12	2016-11-17	Cutting Edge Medical Solutions, Llc	Palmitoylethanolamide compositions
ITUB20153066A1 (it) *	2015-08-11	2017-02-11	Graal S R L	Composizione alimentare e/o nutraceutica contenente pea
EP3334416A1 (en)	2015-08-11	2018-06-20	Eyesiu Medicines B.V.	Pegylated lipid nanoparticle with bioactive lipophilic compound
ITUB20154849A1 (it) *	2015-10-30	2017-04-30	Epitech Group S P A	ADELMIDROL PER L'USO NELLE PATOLOGIE CARATTERIZZATE DA INSUFFICIENTE AGONISMO DEL RECETTORE PPAR-gamma
ES2580508B1 (es) *	2016-04-11	2018-09-12	Servicio Andaluz De Salud	Composiciones para la prevención y/o tratamiento de los trastornos por uso de alcohol.
NL2017559B1 (en) *	2016-09-30	2018-04-10	Vanderbilt Science Holding Ltd	Method for preparing pulverized palmitoylethanolamide particles, particles obtainable by the method, and apharmaceutical or neutraceutical composition comprising saidparticles
CN106478445A (zh) *	2016-11-07	2017-03-08	华中药业股份有限公司	一种非那西丁微粉的制备方法
EP3417846A1 (en)	2017-06-19	2018-12-26	Gifar Srl	Food and/or nutraceutical composition
IT201700068608A1 (it) *	2017-06-20	2018-12-20	Neilos S R L	Composizione per trattamento o prevenzione di una malattia neurodegenerativa
MY172113A (en) *	2017-07-05	2019-11-14	Frimline Private Ltd	A pharmaceutical composition for neuropathic pain
SG10201807034XA (en)	2017-09-05	2019-04-29	Frimline Private Ltd	A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease
IT201800003912A1 (it) *	2018-03-26	2019-09-26	Innovet Italia Srl	N-palmitoil-d-glucosamina in forma micronizzata
IT201800004439A1 (it) *	2018-04-12	2019-10-12		ASSOCIAZIONE DI CURCUMA (Curcuma longa L.), PALMITOILETANOLAMIDE (PEA) E L-TRIPTOFANO
WO2021048871A1 (en) *	2019-09-15	2021-03-18	Celagenex Research (India) Pvt. Ltd.	Synergistic bioactive compositions for treating neurological disorders
EP3838346A1 (en) *	2019-12-20	2021-06-23	Chemo Research SL	Soft gelatin capsules comprising palmitoylethanolamide and alpha-lipoic acid
US11684600B2 (en) *	2020-03-04	2023-06-27	Compact Disc Incorporated	Composition of active agents to positively affect a robust mammalian endocannabinoid system tone to better address age related discomfort
IT202000007831A1 (it)	2020-04-14	2021-10-14	Epitech Group S P A	Adelmidrol per l’uso nel trattamento della fibrosi polmonare
GR20200100479A (el) *	2020-08-13	2022-03-09	Pharma Unimedis Ike,	Συμπληρωμα διατροφης για την προληψη και/ή τη θεραπεια του πονου και/ή νευροπαθειων
CN115052587B (zh) *	2020-12-29	2024-05-10	汉义生物科技（北京）有限公司	一种***素泡腾制剂及其制备方法
IT202100006494A1 (it) *	2021-03-18	2022-09-18	Epitech Group S P A	N-palmitoil-etanolamide per l’uso nella prevenzione del carcinoma colo-rettale
IT202100015278A1 (it)	2021-06-11	2022-12-11	Epitech Group S P A	Composizione di n-palmitoil-etanolamide e baicaleina in forma comicronizzata
IT202100024464A1 (it) *	2021-09-23	2023-03-23	Epitech Group S P A	N-palmitoil-etanolamide e acido docosaesaenoico per l’uso nel trattamento del disturbo dello spettro autistico e di altre sindromi depressive
WO2023133555A2 (en) *	2022-01-10	2023-07-13	Zilker Sciences Llc	Palmitoylethanolamide treatment for covid-19-related inflammation
EP4289421A1 (en) *	2022-06-07	2023-12-13	Erbozeta S.p.A.	Combination of palmitoylethanolamide (pea) and melatonin for the treatment of mast cell hyper-reactivity
EP4331577A1 (en)	2022-08-30	2024-03-06	Unifarco S.p.A.	A nutraceutic tablet comprising palmitoylethanolamide

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2627696B1 (fr)	1988-02-26	1991-09-13	Fournier Innovation Synergie	Nouvelle forme galenique du fenofibrate
WO1989011335A1 (en)	1988-05-17	1989-11-30	Liposome Technology, Inc.	Preparation of uniform-size liposomes and other lipid structures
IT1252865B (it)	1991-12-31	1995-06-28	Lifegroup Spa	N-acilderivati di aminoalcooli attivi come autocoidi locali ed utilizzabili nella terapia dei processi autoimmuni
US5679667A (en) †	1992-04-24	1997-10-21	Lifegroup S.P.A.	Aminoalcohols-N-Acyl derivatives as therapeutical agents against the neurogenic endoneural edema of the peripheral nerve
WO1994028876A1 (en)	1993-06-07	1994-12-22	Advanced Therapies, Inc.	Liposome powders
US5622715A (en)	1994-06-10	1997-04-22	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Method of improving renal function
US5567439A (en) *	1994-06-14	1996-10-22	Fuisz Technologies Ltd.	Delivery of controlled-release systems(s)
IT1271266B (it) *	1994-12-14	1997-05-27	Valle Francesco Della	Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
US5874029A (en)	1996-10-09	1999-02-23	The University Of Kansas	Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
IT1302264B1 (it) †	1998-09-24	2000-09-05	Innovet Italia Srl	Derivati a struttura n-acil vanillinamidica in grado di attivare irecettori periferici dei cannabinoidi
WO2001010434A1 (en)	1999-08-06	2001-02-15	Innovet Italia S.R.L.	Pharmaceutical compositions containing n-palmitoylethanolamide and use thereof in the veterinary field
CA2595004A1 (en) *	2005-01-18	2006-07-27	Kyoto University	Remedy for nerve cell regeneration
DE602006013787D1 (de) *	2006-03-28	2010-06-02	Epitech Group Srl	Eine Pharmazeutische Zusammensetzung zur Behandlung von Pathologien, die durch die allgemeine Immunantwort verursacht werden
NZ552290A (en) *	2006-12-21	2009-05-31	Bomac Research Ltd	Tablet fomulation
CN102186459A (zh)	2009-09-07	2011-09-14	晶源集团股份责任有限公司	含有超微粒化十六酰胺乙醇的组合物

2009
- 2009-09-07 CN CN2009801409003A patent/CN102186459A/zh active Pending
- 2009-09-07 AU AU2009352080A patent/AU2009352080B2/en active Active
- 2009-09-07 JP JP2012527452A patent/JP5746178B2/ja active Active
- 2009-09-07 PT PT141574210T patent/PT2796129E/pt unknown
- 2009-09-07 CA CA2738117A patent/CA2738117C/en active Active
- 2009-09-07 ES ES09741462T patent/ES2547133T5/es active Active
- 2009-09-07 PL PL14157421T patent/PL2796129T3/pl unknown
- 2009-09-07 WO PCT/IT2009/000399 patent/WO2011027373A1/en active Application Filing
- 2009-09-07 KR KR1020127008978A patent/KR101662871B1/ko active IP Right Grant
- 2009-09-07 BR BRPI0919753A patent/BRPI0919753B8/pt active IP Right Grant
- 2009-09-07 EP EP09741462.7A patent/EP2475352B2/en active Active
- 2009-09-07 ES ES14157421.0T patent/ES2548190T3/es active Active
- 2009-09-07 PT PT97414627T patent/PT2475352E/pt unknown
- 2009-09-07 CN CN201610542680.9A patent/CN106138022A/zh active Pending
- 2009-09-07 US US13/120,408 patent/US8470373B2/en active Active
- 2009-09-07 EP EP14157421.0A patent/EP2796129B1/en active Active
- 2009-09-07 PL PL09741462T patent/PL2475352T5/pl unknown
2010
- 2010-09-06 AR ARP100103257A patent/AR078159A1/es not_active Application Discontinuation
2013
- 2013-06-24 US US13/925,435 patent/US8663701B2/en active Active
2015
- 2015-09-16 CY CY20151100814T patent/CY1116695T1/el unknown
- 2015-09-16 CY CY20151100815T patent/CY1116698T1/el unknown
2019
- 2019-08-09 AR ARP190102266A patent/AR115939A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP2796129A1 (en)	2014-10-29
CY1116698T1 (el)	2017-03-15
EP2475352A1 (en)	2012-07-18
CN106138022A (zh)	2016-11-23
PL2796129T3 (pl)	2015-11-30
JP2013503855A (ja)	2013-02-04
EP2475352B2 (en)	2018-09-05
JP5746178B2 (ja)	2015-07-08
BRPI0919753A2 (pt)	2015-12-08
US8470373B2 (en)	2013-06-25
CA2738117A1 (en)	2011-03-10
ES2547133T5 (es)	2019-02-15
EP2475352B1 (en)	2015-06-17
BRPI0919753B1 (pt)	2020-12-29
AR115939A2 (es)	2021-03-17
WO2011027373A1 (en)	2011-03-10
US20110171313A1 (en)	2011-07-14
EP2796129B1 (en)	2015-06-17
PL2475352T3 (pl)	2016-01-29
AU2009352080A1 (en)	2013-06-06
US8663701B2 (en)	2014-03-04
KR101662871B1 (ko)	2016-10-05
AR078159A1 (es)	2011-10-19
ES2548190T3 (es)	2015-10-14
CA2738117C (en)	2016-12-06
CY1116695T1 (el)	2017-03-15
US20130280333A1 (en)	2013-10-24
CN102186459A (zh)	2011-09-14
BRPI0919753B8 (pt)	2021-05-25
PL2475352T5 (pl)	2019-02-28
ES2547133T9 (es)	2016-01-22
PT2475352E (pt)	2015-10-13
AU2009352080B2 (en)	2015-12-24
ES2547133T3 (es)	2015-10-02
KR20120093861A (ko)	2012-08-23

Publication	Publication Date	Title
PL2475352T3 (pl)	2016-01-29	Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji
GB0908129D0 (en)	2009-06-24	Composition
GB0918450D0 (en)	2009-12-09	Composition
GB0905863D0 (en)	2009-05-20	Novel composition
ZA201107839B (en)	2012-12-27	Composition
EP2409997A4 (en)	2014-01-08	REDOX-HARDENING COMPOSITION
GB0911428D0 (en)	2009-08-12	Composition
ZA201107838B (en)	2013-01-30	Composition
GB0909362D0 (en)	2009-07-15	Composition
GB0908642D0 (en)	2009-06-24	Composition
HK1164356A1 (en)	2012-09-21	Composition
IL216395A0 (en)	2012-01-31	Prothrombic complex composition
HK1169306A1 (en)	2013-01-25	Composition having lipolysis-promoting effect
EP2394634A4 (en)	2012-08-29	HESPERIDO-CONTAINING COMPOSITION
GB0906779D0 (en)	2009-06-03	Composition
GB0922389D0 (en)	2010-02-03	composition
GB0904941D0 (en)	2009-05-06	Composition
EP2444061A4 (en)	2015-08-05	COMPOSITION CONTAINING APIGENIN
GB0911294D0 (en)	2009-08-12	Composition
GB0904942D0 (en)	2009-05-06	Composition
GB201006350D0 (en)	2010-06-02	Composition
GB0918590D0 (en)	2009-12-09	Composition
GB0903688D0 (en)	2009-04-15	Composition
GB0922133D0 (en)	2010-02-03	Composition
GB0902959D0 (en)	2009-04-08	Composition